Skip to main content

Table 1 Characteristics of the patients with COVID-19

From: A continuous intravenous insulin infusion protocol to manage high-dose methylprednisolone-induced hyperglycemia in patients with severe COVID-19

  Total non-protocol protocol p
(N = 158) (N = 14) (N = 144)
Age,median (IQR) 68.5 (56–74.3) 60 (50–73) 68 (56–74.8) 0.263
Sex, n (%)
    Male 107 (68) 10 (71) 97 (67)  
    Female 51 (32) 4 (29) 47 (33) 0.756
BMI (kg/m2)(IQR) 25 (22.8–259) 24.1 (20.6–28.2) 25.2 (22.9–27.9) 0.345
P/F ratio after intubation (IQR) 203 (164–259) 213 (182.5–267) 198 (162.5–259.5) 0.343
APACHE ΙΙ score (IQR) 12 (9–14) 9 (5–13) 12 (9–15) 0.019
pre-existing diabetes, n (%) 44 (27.8) 1 (7) 43 (29.9) 0.07
HbA1c, median (IQR) 6.2 (5.8–7.2) 6.6 (6.0–7.8) 6.2 (5.8–7.2) 0.233
Intubation, n (%) 158 (100) 14 (100) 144 (100) -
Anti-viral drug
  before admission
    Favipiravir, n(%) 51 (32) 0 (0) 51 (35) -
  after admission
    Favipiravir, n(%) 86 (54) 14 (100) 72 (50) -
    Remdesivir, n(%) 9 (6) 0 (0) 9 (6) -
Steroid treatment
  before admission
    Dexamethasone, n (%) 57 (36) 0 (0) 57 (40) -
    Methylprednisolone, n (%) 34 (22) 0 (0) 34 (24) -
  after admission
    Methylprednisolone, n (%) 155 (98) 14 (100) 141 (98)  
ECMO, n (%) 2 (1) 1 (7) 1 (1)  
Mortality, n (%) 20 (13) 1 (7) 19 (13) 0.516